Skip to content

Study · Not a test of the peptide alone · 1996

2 results

Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089.

Vink-van Wijngaarden T, Pols HA, Buurman CJ, Birkenhäger JC, van Leeuwen JP

European journal of cancer (Oxford, England : 1990)1 May 1996Cited by 33 (Europe PMC)

PMID9081364 (opens in a new tab)DOI10.1016/0959-8049(95)00647-8 (opens in a new tab)PepBankPUB-09081364
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 LR3.

  1. 01LabNot a test of IGF-1 LR3 aloneIn vitro (cells)Activity measurement

    In MCF-7 human breast cancer cells, long R3 IGF-I stimulated cell growth to a degree similar to insulin.

    In plain wordsIn breast cancer cells in the lab, long R3 IGF-I stimulated growth about as much as insulin did.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseMCF-7 cell growth stimulation by long R3 IGF-I
    Study

    humann: not reported in source

    MCF-7 human breast cancer cells
    Comparator
    Insulin
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    In order to avoid interference of IGF-binding proteins (IGF-BPs), we used an analogue of IGF-I, long R3 IGF-I, which stimulated MCF-7 cell growth similar to insulin.
    1 context sentence
    Summary · context
    The oestrogen receptor-positive MCF-7 human breast cancer cells used in this study are able to grow autonomously and their growth is stimulated by insulin.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  2. 02LabNot a test of IGF-1 LR3 aloneIn vitro (cells)Efficacy outcome

    In MCF-7 breast cancer cells, 1,25-(OH)2D3 and the analogue EB1089 completely inhibited the growth stimulation by insulin and long R3 IGF-I.

    In plain wordsIn breast cancer cells in the lab, vitamin D compounds completely blocked the growth that insulin and long R3 IGF-I caused.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseGrowth stimulation by insulin and long R3 IGF-I after 1,25-(OH)2D3 or EB1089
    Study

    humann: not reported in source

    MCF-7 human breast cancer cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    The growth stimulation by insulin and by long R3 IGF-I was completely inhibited by 1,25-(OH)2D3 and EB1089.
    1 context sentence
    Summary · context
    The oestrogen receptor-positive MCF-7 human breast cancer cells used in this study are able to grow autonomously and their growth is stimulated by insulin.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.